You are here

P&T June 2013

Features

Part 2: Potential Concerns and Challenges for P&T Committees
P&T committee members need a lot more information before they can evaluate the efficacy and safety, interchangeability, and cost-effectiveness of biosimilar products for inclusion on formularies.
A Review of Treatment Options With a Focus on Pharmacological Approaches
Oral contraceptives, antidiabetes drugs, and statins are some of the therapies used to address the symptoms of this complex hormonal condition. Weight loss and surgery may also be beneficial as non-drug options.
Pharmacovigilance Forum
A Potentially Serious and Underreported Problem
There have been many published reports of possible cases of drug-induced pancreatitis. In addition, some disease states and patient characteristics predispose particular populations to the development of this condition. Three case histories are presented.

Departments

Medication Errors
Generic drugs with multiple brand names can cause confusion.
Prescription: Washington
New medicare Part D rules and possible cuts to hospitals

FDA approvals, drug indications, and updates

Extended-release carbinoxamine maleate oral suspension (Karbinaler) for allergicrhinitis; brinzolamide 1.0%/brimonidine tartrate 0.2% ophthalmic suspension (simbrinza) for open-angle glaucoma and ocular hypertension; and cysteamine bitartrate (Procysbi) for nephropathic cystinosis

Drug Forecast
Dextromethorphan/quinidine (nuedexta) for pseudobulbar affect